Health
The Next Shot: How GLP-1 Research Is Rewriting the Future of Weight Loss Medicine
With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.
Key Takeaways
- One in eight U.S. adults now takes GLP-1 medications like Ozempic or Wegovy for weight management
- GLP-1 drugs activate the brain's stress response system, elevating cortisol and causing muscle loss
- Patients who stop treatment experience rebound overeating driven by chronically stimulated stress hormones
- Combination therapy with anti-CRH antibodies preserved muscle and maintained weight loss after drug discontinuation
- Human clinical trials of the combination approach are being planned pending partnership development
DE
DT Editorial AI··via medicalxpress.com